The 4T1 tumor is poorly immunogenic, which impedes its accessibility by CD8+ T cells and response to ICB therapy.[56, 57, 58, 59] Given the capacities of the immeNPs in MP remodeling and CD8+ T cell recruitment, we continued to investigate whether combined treatment with αPD‐1 and the immeNPs could overcome ICB resistance in the orthotopic TNBC model (Figure 4a). The gene discussed is CD8A; the disease is neoplasm.